ALLMedicine™ Ulcerative Colitis Center

Sep 18th, 2020 - Chronic non‑specific inflammatory cell infiltration of the colon is generally considered to be the cause of ulcerative colitis (UC). Gloeostereum incarnatum (GI), a fungus rich in amino acids and fatty acids, exhibits a variety of biological funct...

Sep 18th, 2020 - STRUCTURED ABSTRACTPurpose/aim of the study: Dry eye syndrome is known to develop from several systemic inflammatory diseases. Although dry eye may develop due to extraintestinal complications of ulcerative colitis (UC), the pathogenesis is not we...

Sep 18th, 2020 - Tofacitinib for the Treatment of Ulcerative Colitis, Alopecia Universalis, and Atopic Dermatitis: One Drug, Three Diseases.|2020|Honap S,Cookson H,Sharma E,Samaan MA,Irving PM,|

Sep 18th, 2020 - Medications are major cost drivers in the treatment of patients with inflammatory bowel disease. Recent analyses suggest that there is no added efficacy in continuing nor harm in stopping 5-aminosalicylate (ASA) therapy in patients with inflammato...

Sep 17th, 2020 - Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disease of the gastrointestinal tract, consisting of ulcerative colitis (UC) and Crohn's disease (CD). Gut microbiota and their metabolites may play a role in the pathogen of...

Mar 9th, 2020 - Spotlight: Management of Moderate-to-Severe Ulcerative Colitis.|2020|Feuerstein JD,Isaacs KL,Schneider Y,Siddique SM,Falck-Ytter Y,|

Jan 16th, 2020 - A subset of patients with ulcerative colitis (UC) present with, or progress to, moderate to severe disease activity. These patients are at high risk for colectomy, hospitalization, corticosteroid dependence, and serious infections. The risk of lif...

Jan 16th, 2020 - AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.|2020|Feuerstein JD,Isaacs KL,Schneider Y,Siddique SM,Falck-Ytter Y,|

Oct 29th, 2019 - Management of ulcerative colitis: summary of updated NICE guidance.|2019|Abdulrazeg O,Li B,Epstein J, ,|drug therapy,methods,therapeutic use,drug therapy,drug therapy,

Oct 20th, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration's (FDA) approval of STELARA® (ustekinumab) for the treatment of adult patients with moderately to severely active ulcerative colitis. T...

Sep 18th, 2020 - Chronic non‑specific inflammatory cell infiltration of the colon is generally considered to be the cause of ulcerative colitis (UC). Gloeostereum incarnatum (GI), a fungus rich in amino acids and fatty acids, exhibits a variety of biological funct...

Sep 18th, 2020 - STRUCTURED ABSTRACTPurpose/aim of the study: Dry eye syndrome is known to develop from several systemic inflammatory diseases. Although dry eye may develop due to extraintestinal complications of ulcerative colitis (UC), the pathogenesis is not we...

Sep 18th, 2020 - Tofacitinib for the Treatment of Ulcerative Colitis, Alopecia Universalis, and Atopic Dermatitis: One Drug, Three Diseases.|2020|Honap S,Cookson H,Sharma E,Samaan MA,Irving PM,|

Sep 18th, 2020 - Medications are major cost drivers in the treatment of patients with inflammatory bowel disease. Recent analyses suggest that there is no added efficacy in continuing nor harm in stopping 5-aminosalicylate (ASA) therapy in patients with inflammato...

Sep 17th, 2020 - Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disease of the gastrointestinal tract, consisting of ulcerative colitis (UC) and Crohn's disease (CD). Gut microbiota and their metabolites may play a role in the pathogen of...

Jun 2nd, 2020 - (Reuters) - U.S. drugmaker Bristol Myers Squibb Co said on Tuesday its treatment Zeposia, which it gained through its $74 billion buyout of Celgene last year, met the main goals of a late-stage study testing it in patients with an inflammatory bow...

May 20th, 2020 - (Reuters) - Gilead Sciences Inc (GILD.O) and partner Galapagos NV (GLPG.AS) said on Wednesday only a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a pivotal study testing it in ulcerative colitis pa...

Mar 13th, 2020 - For moderate to severe ulcerative colitis, treatment with any one of the leading biologic agents is superior to no treatment at all. To maintain long-term remission, the Janus kinase inhibitor tofacitinib 5 mg twice daily is preferred for most pat.

Mar 1st, 2020 - In late January, the Crohn’s & Colitis Foundation teamed with AGA to present the Crohn’s & Colitis Congress® in Austin, Tex. Each year, this is the premier gathering for IBD experts and the rest of us to catch up on the substantial progress we are.

Feb 27th, 2020 - Researchers have found three potential gut mechanisms linked to secondary bile acid (SBA) deficiencies implicated in intestinal inflammation in ulcerative colitis (UC), and reported that supplementation may aid in restoring bile acid levels and po.